Skip to main content
Log in

Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

In 12 healthy male volunteers, molsidomine 1, 2 and 4 mg i.v. increased resting heart rate and decreased systolic blood pressure, the latter still being affected after 8 hours. After single oral doses of 1 and 2 mg, systolic pressure tended to be reduced for 90 minutes and exercise heart rate tended to be increased. After oral treatment with 2 mg molsidomine three times daily for 1 week, the pharmacokinetic parameters and the effects on heart rate and blood pressure after the final dose were not different from those after the first dose. The terminal half-life was independent of dose and route of administration. Clearance and distribution volume were not dose-dependent. The bioavailability of a 2 mg oral dose of molsidomine was 44%. Inter-individual variation in heart rate, blood pressure and pharmacokinetics was observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Milei J, Vazquez A, Lemus J (1980) Double-blind controlled trial of molsidomine in hypertension. Eur J Clin Pharmacol 18: 231–235

    Google Scholar 

  2. Guerchicoff S, Vazquez A, Kunik H, Drajer S, Diaz F (1978) Acute double blind trial of a new anti-anginal drug: Molsidomine. Eur J Clin Pharmacol 13: 247–250

    Google Scholar 

  3. Majid PA, DeFeyter PJF, Van der Wall EE, Wardeh R, Roos JP (1980) Molsidomine in the treatment of patients with angina pectoris. Acute hemodynamic effects and clinical efficacy. N Engl J Med 302: 1–6

    Google Scholar 

  4. Dell D, Chamberlain J (1978) Determination of molsidomine in plasma by high performance liquid column chromatography. J Chromatogr 146: 465

    Google Scholar 

  5. Rowland M, Tozer T (1980) Clinical pharmacokinetics: Concepts and applications. Sections I and II. Lea and Febiger, Philadelphia, pp 9–134

    Google Scholar 

  6. Kirk RE (1968) Experimental design. Procedures for the behavioral sciences. Brooks/Cale Publishing Company, Belmont, CA, USA

    Google Scholar 

  7. Duncan DB (1955) Multiple range and multiple F-tests. Biometrics 11: 1–42

    Google Scholar 

  8. Shapiro SS, Wilk MB (1965) Analysis of variance test for normality (complete samples). Biometrics 52: 591–611

    Google Scholar 

  9. Yates F (1933) The analysis of replicated experiments when the field results are uncomplete. Emp J Exp Agr 1: 129–142

    Google Scholar 

  10. Karsch KR, Rentrop KP, Blanke H, Kreuzer H (1978) Haemodynamic effects of molsidomine. Eur J Clin Pharmacol 13: 241–245

    Google Scholar 

  11. Aptecar M, Otero y Garzon CA, Vasquez A, Varini S, Collia L, Esteguy A, Caruso S (1981) Hemodynamic effects of molsidomine vasodilator therapy in acute myocardial infarction. Am Heart J 101: 369–373

    Google Scholar 

  12. Vogt A, Kreuzer H (1982) Comparative study of haemodynamic effects of oral molsidomine and isosorbide dinitrate in man. Eur J Clin Pharmacol 23: 11–14

    Google Scholar 

  13. Ostrowski J (1979) Zur Pharmakokinetik von Corvaton (Molsidomine) beim Menschen. In: Lochner W, Bender F (eds) Molsidomin. Urban & Schwarzenberg, München Wien Baltimore, pp 69–73

    Google Scholar 

  14. Weidemann H, Ostrowski J, Voegele D, Schalla U, Resag K (1982) Ergebnisse von Belastungs-EKG-Serienuntersuchungen in Abhängigkeit der Molsidomin-Blutspiegel bei Molsidomin retard 8 mg im Vergleich zu Molsidomin 2 mg. Herz/Kreislauf 5: 268–273

    Google Scholar 

  15. Strasser R, Klepzig H, Ostrowski J, Resag K (1983) Wirkung von Molsidomin bei koronarer Herzkrankheit nach oraler und sublingualer Gabe. Klinische-pharmakokinetische Korrelationstudie. Dtsch Med Wochenschr 125: 156

    Google Scholar 

  16. Rohl D, Lehmann K (1980) Molsidomin in Ergometerversuch. Dtsch Med Wochenschr 105: 1216–1219

    Google Scholar 

  17. Ostrowski J, Schweizer P, Erpel R, Claus G, Resag K (1981) Correlation of pharmacokinetic data to clinical effect of molsidomine. First European Congress of Biopharmacology and Pharmacokinetics. Clemont-Ferraud 1–3 April 1981. Vol 3: 418–424

  18. Tanayna S, Nakai Y, Fujita T, Suzoki Z (1974) Biotransformation of Molsidomine, a new anti-anginal agent in rates. Xenobiotica 4: 175

    Google Scholar 

  19. Rowland M, Tozer T (1980) Clinical pharmacokinetics: Concepts and applications. Lea and Febiger, Philadelphia, chapter 14, p 197

    Google Scholar 

  20. Oltmanns D, Friedmann W, Ostrowski J (1982) Zur Pharmakokinetik von Molsidomin in höherer Dosierung bei der Behandlung des frischen Herzinfarkts. Herz-Medizin 5: 141

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergstrand, R., Vedin, A., Wilhelmsson, C. et al. Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study. Eur J Clin Pharmacol 27, 203–208 (1984). https://doi.org/10.1007/BF00544046

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00544046

Key words

Navigation